Panreactive Antibody Screen in an Actively Bleeding Patient
Mr. R, 64, is admitted with melena, a hemoglobin of 6.6 g/dL, and heart rate 118 with normal blood pressure. He is group O Rh-positive and received 2 units of red cells 9 days ago for the same problem. His antibody screen is 3+ in all three screening cells at the antihuman globulin phase, and the autocontrol is also 3+. The direct antiglobulin test is 3+ with anti-IgG and negative with anti-C3d, and an eluate prepared from his red cells is panreactive. The blood bank has 4 units of O-positive red cells on the shelf. The gastroenterologist wants 2 units immediately, the patient is actively bleeding, and the technologist on duty has never done an adsorption and is working alone on nights.
1. What is the most likely explanation for these findings, and what single additional test would best exclude a coexisting alloantibody that the autoantibody could be hiding?
Read the worked answer
The pattern is a warm autoantibody: a 3+ panreactive screen, a 3+ autocontrol, a DAT that is strongly positive with anti-IgG but negative with anti-C3d, and a panreactive eluate. Cold agglutinin and antibody-to-medication patterns would be expected to show complement on the DAT or to disappear with treatment.
The reason this matters is that an alloantibody can sit underneath a warm autoantibody and be invisible on the panel, so the screen alone cannot be trusted.
Autoadsorption would normally be the cleanest approach, but he was transfused 9 days ago, so his circulation contains donor cells that will adsorb out alloantibodies and give a false-negative result. Alloadsorption with 3 to 4 selected allogeneic red cells is the correct test: choose cells that collectively lack the high-incidence and immunogenic antigens (C, c, E, e, K, Jka, Jkb, Fya, Fyb, S, s, M, N, Lea). Retest the adsorbed serum against a full panel. If reactivity disappears, the autoantibody is the only antibody. If it persists, work up the residual specificity and select antigen-negative units.
2. The adsorption will take at least 3 hours. What should be transfused now, and how should the units be labeled and released?
Read the worked answer
At a hemoglobin of 6.6 g/dL with ongoing melena and tachycardia, the risk of withholding blood exceeds the risk of transfusing through a warm autoantibody. The autoantibody is directed at the patient's own cells, so it does not cause an acute hemolytic reaction to donor units; the real hazard is an unrecognized alloantibody, which is exactly why the adsorption is being run.
Practical steps:
- Give 1 unit, reassess, then decide on the second, rather than committing to 2 units at once.
- Phenotype (or genotype) the patient's red cells from the pretransfusion sample so you know which antigens he lacks; if a phenotype is available before release, honor it. If not, do not let that delay the first unit.
- The crossmatch will be incompatible. Release the units as least incompatible, with the incompatibility documented and the clinician notified that the units are being issued over a positive crossmatch because of a warm autoantibody.
- ABO and Rh identical units are acceptable; there is no reason to reserve O-negative units for an O-positive patient.
After transfusion, monitor for a falling hemoglobin, rising bilirubin and LDH, and falling haptoglobin to detect any hemolytic component.
3. The adsorption is completed and the adsorbed serum is nonreactive against a 16-cell panel. What should be recorded for this patient's future admissions, and what is the most important pitfall to avoid next time?
Read the worked answer
The nonreactive adsorbed serum means no alloantibody was detectable under the autoantibody at this time, so the record should document warm autoantibody with a negative alloadsorption and no identifiable alloantibody.
The pitfall is that a negative adsorption today does not mean the antibody screen can be ignored later. The antibody screen will keep coming up panreactive, and a new alloantibody appearing months from now can be masked the same way. On future admissions:
- Repeat the adsorption if the patient has been transfused within the previous 3 months, since autoadsorption is unreliable during that window.
- Phenotype or genotype the patient once, clearly, and file the phenotype so antigen-negative units can be selected without repeating the work.
- Continue to transfuse the minimum number of units that relieve symptoms. Transfusion is the main stimulus for new alloantibody formation in these patients, and each exposure makes the next workup harder.